Impel Pharmaceuticals is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with unmet medical needs, with an initial focus on the Central Nervous System. Co. has launched Trudhesa for the acute treatment of migraine headaches with or without aura in adult patients. Co. is developing several product candidates, including INP105 for the acute treatment of agitation and aggression in patients with Autism Spectrum Disorder. Co.'s pipeline of proprietary product candidates also includes INP107 for the treatment of OFF episodes in Parkinson's Disease. The IMPL stock yearly return is shown above.
The yearly return on the IMPL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMPL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|